Ovidiu Bălăcescu

EDUCATION:

1999-2006            PhD in Pharmacy, Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, Romania

1989-1994            B.Sc in Chemistry and Physics, Faculty of Chemistry and Chemical Engineering, Babes-Bolyai University Cluj-Napoca, Romania

RESEARCH EXPERIENCE:

10.2007-present               Senior researcher, at Functional Genomics and Experimental Pathology Department, The Oncology Institute “Prof. Dr. I. Chiricuta”, Cluj-Napoca, Romania

11.1996-10.2007                Researcher at Experimental Pathology Department, The Oncology Institute “Prof. Dr. I.Chiricuta”, Cluj-Napoca, Romania

06.2003-05.2004                PhD Marie-Curie fellow (QLGA-1999-50406) at Functional Genomics Department, Institute Gustave Roussy, Villejuif, France

04.2002-07.2002                Internship (World Bank Grant) at the Department of Radiosensitivity UPRES EA 27-10, Gustave Roussy Institute, Villejuif, France

05.1994-10.1996                Volunteer at Radiotherapy and Medical Oncology Department, The Oncology Institute “Prof. Dr. I.Chiricuta”, Cluj-Napoca, Romania

Volunteer at   Experimental Pathology Department, The Oncology Institute “Prof. Dr. I.Chiricuta”, Cluj-Napoca, Romania

INTERNATIONAL AND NATIONAL GRANTS (MANAGEMENT):

2012-1015            Project Director in national project -Analysis of microRNA biomarkers as predictive values for cervical cancer treatment, in relationship with environmental exposure to arsenic, phthalates and ETS (Cervicall-arsen-array no 96/2012)

2008-2011            Project Director in national project – The identification of the transcriptomic molecular profiles in advanced stage cervical cancer using functional genomics studies (Cervixarray 42-160/2008)

2007-2010            Project Director in national project – Identification trough microarray technology of non-invasive predictive tumoral biomarkers in prostate cancer (IDEI: ID_314/2007)

2007-2010            Manager in national project – Molecular profile definition (transcriptomics) in prediction of clinical status in breast cancers resistant to antracyclines. Metastatic disease definition in relation to primary tumor (Breastomics 41-029/2007)

2004-2008            Member in more than 10 national projects granted by Medical Academy of Science and Minister of Science and Research from Romania

2003-2004

SELECTION OF PUBLICATIONS IN GENOMICS AND CANCER RESEARCH:

1.            Virag P, Fischer-Fodor E, Perde-Schrepler M, Brie I, Tatomir C, Balacescu L, Berindan-Neagoe I, Victor B, Balacescu O. Oxaliplatin induces different cellular  and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. BMC Genomics. 2013 Jul 16;14:480

2.            Chirila DN, Popp RA, Balacescu O, Turdeanu NA, Constantea NA, Pop TR, Vesa SC, Ciuce C. GST gene variants in synchronous colorectal cancers and synchronous association of colorectal cancers with other cancers. Chirurgia (Bucur). 2013 May-Jun;108(3):365-71

3.            Berindan-Neagoe I, Braicu C, Pileczki V, Cojocneanu Petric R, Miron N, Balacescu O, Iancu D, Ciuleanu T. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells. J Gastrointestin Liver Dis. 2013 Mar;22(1):37-43

4.            Miron N, Susman S, Balacescu O, Buiga R, Berindan-Neagoe I, Cristea V, Balacescu L, Manolescu V, Ciuleanu TE. Novel cellular and molecular approaches to stratification and treatment of colorectal cancer. J Gastrointestin Liver Dis. 2012 Dec;21(4):413-21

5.            Berindan-Neagoe I, Braicu C, Tudoran O, Balacescu O, Irimie A. Early apoptosis signals induced by a low dose of epigallocatechin 3-gallate interfere with apoptotic and cell death pathways. J Nanosci Nanotechnol. 2012 Mar;12(3):2113-9

6.            Berindan-Neagoe I, Chiorean R, Braicu C, Florian IS, Leucuta D, Crisan D, Cocis A, Balacescu O, Irimie A. Quantitative mRNA expression of genes involved in angiogenesis, coagulation and inflammation in multiforme glioblastoma tumoral tissue versus peritumoral brain tissue: lack of correlation with clinical data. Eur Cytokine Netw. 2012 Jun;23(2):45-55